Lexology December 15, 2023
Ropes & Gray LLP

The past year has seen unprecedented growth and development of artificial intelligence (“AI”) tools, which have been significantly propelled by the rapid deployment of generative AI (“GenAI”) tools. The health care and life sciences industries have increasingly sought the use of AI and GenAI tools to promote innovation, efficiency and precision in the delivery of treatment and care, as well as in the production of biologics and medical devices. For example, AI tools may more accurately predict and analyze diagnostic test results and develop personalized treatments than traditional tools; may improve clinical trial design, eligibility screening and data analysis; may be used as a diagnostic tool in a clinical trial designed to assess the safety or efficacy of a medical...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Congress / White House, Govt Agencies, Regulations, States, Technology
OpenAI’s GPT-5 Model Reportedly Behind Schedule With Uncertain Future
10 AI Predictions For 2025
Three Practical Reasons To Consider AI Agents For Your Organization
Dexcom Adds Generative AI Platform to Its Over-the-Counter CGM
My Medical AI Holiday Wish List

Share This Article